Characterization of test positivity among patients with coronavirus disease 2019 (COVID-19) in three electronic health records databases, February–November 2020

Author:

Saunders-Hastings Patrick,Zhou Cindy Ke,Hobbi Shayan,Wong Hui-Lee,Lloyd Patricia,Boyd Eva,Alawar Nader,Clarke Tainya C.,Beers Jeff,Burrell Timothy,Shoaibi Azadeh

Abstract

Abstract Background Monitoring COVID-19 testing volumes and test positivity is an integral part of the response to the pandemic. We described the characteristics of individuals who were tested and tested positive for SARS-CoV-2 during the pre-vaccine phase of the pandemic in the United States (U.S.). Methods This descriptive study analyzed three U.S. electronic health record (EHR) databases (Explorys, Academic Health System, and OneFlorida) between February and November 2020, identifying patients who received an interpretable nucleic acid amplification test (NAAT) result. Test-level data were used to characterize the settings in which tests were administered. Patient-level data were used to calculate test positivity rates and characterize the demographics, comorbidities, and hospitalization rates of COVID-19-positive patients. Results Over 40% of tests were conducted in outpatient care settings, with a median time between test order and result of 0–1 day for most settings. Patients tested were mostly female (55.6–57.7%), 18–44 years of age (33.9–41.2%), and Caucasian (44.0–66.7%). The overall test positivity rate was 13.0% in Explorys, 8.0% in Academic Health System, and 8.9% in OneFlorida. The proportion of patients hospitalized within 14 days of a positive COVID-19 NAAT result was 24.2–33.1% across databases, with patients over 75 years demonstrating the highest hospitalization rates (46.7–69.7% of positive tests). Conclusions This analysis of COVID-19 testing volume and positivity patterns across three large EHR databases provides insight into the characteristics of COVID-19-tested, COVID-19-test-positive, and hospitalized COVID-19-test-positive patients during the early phase of the pandemic in the U.S.

Funder

U.S. Food and Drug Administration

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health

Reference32 articles.

1. US CDC. Coronavirus disease 2019 (COVID-19): cases in U.S. 2021. Accessed 15 Sept 2021.

2. US FDA. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices: In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 2020. Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2. Accessed 15 Sept 2021.

3. US CDC. Interim Guidance for Antigen Testing for SARS-CoV-2: Evaluating the Results of Antigen Testing for SARS-CoV-2 Atlanta, GA2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html#evaluating-test-results. Accessed 15 Sept 2021.

4. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities. Geneva: World Health Organization; 2021.

5. Grantz KH, Lee EC, D'Agostino McGowan L, Lee KH, Metcalf CJE, Gurley ES, et al. Maximizing and evaluating the impact of test-trace-isolate programs: a modeling study. PLoS Med. 2021;18(4):e1003585.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3